rgd peptide
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2021 (NCT05653245)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibronectin receptor betaINHIBITOR
ITGB1 inhibitor
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06936605 | N/A | Apr 15, 2025 | Minia University |
| NCT06585852 | N/A | Aug 1, 2023 | Al Azhar University |
| NCT05653245 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2021 | Minia University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minia University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1